复旦张江(01349.HK) 公布,旗下盐酸氨酮戊酸口服溶液用粉末用于成人恶性高级别脑胶质瘤患者术中恶性组织可视化的药物上市申请,获得国家药监局受理。该药物的临床试验申请已于2023年12月获批,并于2024年月启动验证性临床研究。(ss/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source Link复旦张江(01349.HK) 公布,旗下盐酸氨酮戊酸口服溶液用粉末用于成人恶性高级别脑胶质瘤患者术中恶性组织可视化的药物上市申请,获得国家药监局受理。该药物的临床试验申请已于2023年12月获批,并于2024年月启动验证性临床研究。(ss/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.